PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

British Journal of Pharmacology

Volumn 161, Issue 5, 2010, Pages 1099-1110

  Leal, J F M ^a   Martinez Diez M ^a   Garcia Hernandez V ^b   Moneo, V ^a   Domingo, A ^b   Bueren Calabuig, J A ^b   Negri, A ^b   Gago, F ^b   Guillen Navarro M J ^a   Aviles P ^a   Cuevas, C ^a   Garcia Fernandez L F ^a   Galmarini, C M ^a  

^a PHARMAMAR S A   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antineoplastic agents; Apoptosis; DNA breaks; Tetrahydroisoquinolines

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALANINE; ANTINEOPLASTIC AGENT; CYSTEINE; GUANINE; PM 01183; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE S PHASE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DNA ADDUCT; DNA DENATURATION; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; DRUG BINDING; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA; DNA ADDUCTS; DNA BREAKS, DOUBLE-STRANDED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS; TETRAHYDROISOQUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958587933     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00945.x     Document Type: Article

References (34)

1. Arai T, Takahashi K, Nakahara S, Kubo A (1980). The structure of a novel antitumor antibiotic, saframycin A. Experientia 36: 1025-1027.
2. Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA et al. (2008). Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res 14: 6449-6455.
3. Aviles PM, Galmarini CM, Cuevas C, Guillen MJ, Frapolli R, Uboldi S et al. (2009). Mechanism of action and antitumor activity of PM01183. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, AACR: Denver, CO, Abstract 2679.
4. Baraldi PG, Cacciari B, Guiotto A, Romagnoli R, Zaid AN, Spalluto G (1999). DNA minor-groove binders: results and design of new antitumor agents. Farmaco 54: 15-25.
5. Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, Perez L et al. (2008). Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 7: 1309-1318.
6. Case DA, Cheatham III, TE, Darden T, Gohlke H, Luo R, Merz Jr., KM et al. (2005). The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
7. David-Cordonnier MH, Gajate C, Olmea O, Laine W, Iglesia-Vicente J, Perez C et al. (2005). DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 12: 1201-1210.
8. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT et al. (2001). Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37: 97-105.
9. Escargueil AE, Poindessous V, Soares DG, Sarasin A, Cook PR, Larsen AK (2008). Influence of irofulven, a transcription-coupled repair-specific antitumor agent, on RNA polymerase activity, stability and dynamics in living mammalian cells. J Cell Sci 121: 1275-1283.
10. Garcia-Nieto R, Manzanares I, Cuevas C, Gago F (2000). Bending of DNA upon Binding of Ecteinascidin 743 and Phthalascidin 650 Studied by Unrestrained Molecular Dynamics Simulations. J Am Chem Soc 122: 7172-7182.
11. Guan Y, Sakai R, Rinehart K, Wang AH (1993). Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean thnicate ecteinascidia turbinata. J Biomol Struct Dyn 10: 793-818.
12. Guirouilh-Barbat J, Antony S, Pommier Y (2009). Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 8: 2007-2014.
13. ® (pm00104) to the lack of a functional nucleotide excision repair system. In: American Association for Cancer Research Annual Meeting. Proceedings: Los Angeles, CA, Abstract 1537.
14. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S (2006). Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 66: 8155-8162.
15. Kishi K, Yazawa K, Takahashi K, Mikami Y, Arai T (1984). Structure-activity relationships of saframycins. J Antibiot (Tokyo) 37: 847-852.
16. Lane JW, Estevez A, Mortara K, Callan O, Spencer JR, Williams RM (2006). Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G. Bioorg Med Chem Lett 16: 3180-3183.
17. Leal JF, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A et al. (2009). Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol 78: 162-170.
18. Manzanares I, Cuevas C, Garcia-Nieto R, Marco E, Gago F (2001). Advances in the chemistry and pharmacology of ecteinascidins, a promising new class of anti-cancer agents. Curr Med Chem Anticancer Agents 1: 257-276.
19. Marco E, David-Cordonnier MH, Bailly C, Cuevas C, Gago F (2006). Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J Med Chem 49: 6925-6929.
20. Moore BM, Seaman FC, Hurley LH (1997). NMR-based model of an Ecteinascidin 743-DNA adduct. J Am Chem Soc 119: 5475-5476.
21. Negri A, Marco E, Garcia-Hernandez V, Domingo A, Llamas-Saiz AL, Porto-Sanda S et al. (2007). Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptide. J Med Chem 50: 3322-3333.
22. Oku N, Matsunaga S, Van Soest RW, Fusetani N (2003). Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp. J Nat Prod 66: 1136-1139.
23. Pabo CO, Sauer RT (1984). Protein-DNA recognition. Annu Rev Biochem 53: 293-321.
24. Pierce JR, Nazimiec M, Tang MS (1993). Comparison of sequence preference of tomaymycin- and anthramycin-DNA bonding by exonuclease III and lambda exonuclease digestion and UvrABC nuclease incision analysis. Biochemistry 32: 7069-7078.
25. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996). DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35: 13303-13309.
26. Rao KE, Lown JW (1992). DNA sequence selectivities in the covalent bonding of antibiotic saframycins Mx1, Mx3, A, and S deduced from MPE.Fe(II) footprinting and exonuclease III stop assays. Biochemistry 31: 12076-12082.
27. Reddy BS, Sharma SK, Lown JW (2001). Recent developments in sequence selective minor groove DNA effectors. Curr Med Chem 8: 475-508.
28. Rinehart K, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Sun F et al. (1990). Ecteinascidins 729, 743, 745, 759A, 759B and 770: potent antitumor agents from the Caribean tunicate Ecteinascidia turbinata. J Org Chem 55: 4512-4515.
29. Rohs R, West SM, Sosinsky A, Liu P, Mann RS, Honig B (2009). The role of DNA shape in protein-DNA recognition. Nature 461: 1248-1253.
30. Seaman FC, Hurley LH (1998). Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: evidence for a dominant role of direct readout via hydrogen bonding. J Am Chem Soc 120: 13028-13041.
31. Soares DG, Escargueil AE, Poindessous V, Sarasin A, De Gramont A, Bonatto D et al. (2007). Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 104: 13062-13067.
32. Susbielle G, Blattes R, Brevet V, Monod C, Kas E (2005). Target practice: aiming at satellite repeats with DNA minor groove binders. Curr Med Chem Anticancer Agents 5: 409-420.
33. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T et al. (2001). Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7: 961-966.
34. Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M et al. (2008). Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44: 609-618.